It is critical that our importation process for therapies include an understanding of impact across a diversity of patient groups, including underserved communities who could greatly benefit from these treatments. That’s why we remain committed to increasing patient diversity within our research and importation programs. This includes leveraging data and digital technology to increase understanding and to inform quality level, quality management, and patient and site selection.
We are also working to strengthen our suppliers diversity programs. For example, our Preferred Firm Program for Legal Services now requires specific diverse staffing commitments for each engagement. We have developed guidance for suppliers, and uphold principles in all suppliers risk management, procurement and supply chain practices.